

A T Pharma Solutions Limited

Annual Report and Unaudited Financial Statements
for the Year Ended 31 July 2017

A T Pharma Solutions Limited

Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u> to <u>3</u>
Notes to the Financial Statements	<u>4</u> to <u>6</u>

A T Pharma Solutions Limited

Company Information

Directors	Mrs A C Ralli-Thomas Mr D A Thomas
Registered office	The Orbit Business Centre Rhydycar Park Merthyr Tydfil Mid Glamorgan CF48 1DL
Accountants	Mitchell Meredith Limited Chartered Accountants The Hawthorns 6 North Road Cardiff CF10 3DU

A T Pharma Solutions Limited
(Registration number: 09696921)
Balance Sheet as at 31 July 2017

	Note	2017 £	2016 £
Fixed assets			
Tangible assets	<u>3</u>	691	-
Current assets			
Debtors	<u>4</u>	8,651	12,403
Cash at bank and in hand		6,243	2,414
		14,894	14,817
Creditors: Amounts falling due within one year	<u>5</u>	(11,662)	(13,446)
Net current assets		3,232	1,371
Total assets less current liabilities		3,923	1,371
Provisions for liabilities		(170)	-
Net assets		<u>3,753</u>	<u>1,371</u>
Capital and reserves			
Called up share capital		2	2
Profit and loss account		3,751	1,369
Total equity		<u>3,753</u>	<u>1,371</u>

The notes on pages 4 to 6 form an integral part of these financial statements.
Page 2

A T Pharma Solutions Limited
(Registration number: 09696921)
Balance Sheet as at 31 July 2017

For the financial year ending 31 July 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 16 February 2018 and signed on its behalf by:

.....

Mrs A C Ralli-Thomas

Director

The notes on pages 4 to 6 form an integral part of these financial statements.
Page 3

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2017

1 General information

The company is a private company limited by share capital incorporated in England and Wales.

The address of its registered office is:

The Orbit Business Centre
Rhydycar Park
Merthyr Tydfil
Mid Glamorgan
CF48 1DL

The principal place of business is:

10 Hardwicke Court
Cardiff
CF5 2LB

These financial statements were authorised for issue by the Board on 16 February 2018.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Furniture, fittings and equipment	20% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2017

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

A T Pharma Solutions Limited

Notes to the Financial Statements for the Year Ended 31 July 2017

3 Tangible assets

	Furniture, fittings and equipment £	Total £
Cost or valuation		
Additions	864	864
At 31 July 2017	864	864
Depreciation		
At 1 August 2016	173	173
At 31 July 2017	173	173
Carrying amount		
At 31 July 2017	691	691

4 Debtors

	2017 £	2016 £
Trade debtors	2,045	10,992
Other debtors	6,606	1,411
Total current trade and other debtors	8,651	12,403

5 Creditors

	Note	2017 £	2016 £
Due within one year			
Amounts owed to group undertakings and undertakings in which the company has a participating interest		62	-
Other creditors		11,600	13,446
		11,662	13,446